Macquarie Group’s Atea Pharmaceuticals AVIR Stock Holding History

Macquarie Group’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-70,000	Closed	-$203K	–	914
2025 Q3	$203K	Hold	70,000	–	–	﹤0.01%	1486
2025 Q2	$252K	Hold	70,000	–	–	﹤0.01%	1524
2025 Q1	$209K	Hold	70,000	–	–	﹤0.01%	1533
2024 Q4	$235K	Hold	70,000	–	–	﹤0.01%	1501
2024 Q3	$235K	Hold	70,000	–	–	﹤0.01%	1543
2024 Q2	$232K	Hold	70,000	–	–	﹤0.01%	1547
2024 Q1	$283K	Hold	70,000	–	–	﹤0.01%	1497
2023 Q4	$214K	Hold	70,000	–	–	﹤0.01%	1545
2023 Q3	$210K	Hold	70,000	–	–	﹤0.01%	1521
2023 Q2	$262K	Hold	70,000	–	–	﹤0.01%	1526
2023 Q1	$235K	Hold	70,000	–	–	﹤0.01%	1541
2022 Q4	$337K	Sell	70,000 -1,504	-2%	-$7.61K	﹤0.01%	1557
2022 Q3	$407K	Hold	71,504	–	–	﹤0.01%	1553
2022 Q2	$508K	Hold	71,504	–	–	﹤0.01%	1589
2022 Q1	$516	Hold	71,504	–	–	﹤0.01%	1643
2021 Q4	$639K	Buy	71,504 +70,000	+4,654%	+$1.09M	﹤0.01%	1631
2021 Q3	$53K	Buy	+1,504	New	+$41.7K	﹤0.01%	2208

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group's AVIR Position: Q4 2025 in Review

Macquarie Group sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 70,000 shares — an estimated $203K sold.

Macquarie Group first reported a position in AVIR in Q3 2021 and held it in 17 quarters. The position peaked at $639K in Q4 2021. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

Macquarie Group reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 70,000 Atea Pharmaceuticals shares in Q4 2025, an estimated $203K.
Macquarie Group first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 17 quarters.
Macquarie Group's Atea Pharmaceuticals position peaked at $639K in Q4 2021.
111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.